R/R CD19-Positive B-Cell Malignancies

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Century Therapeutics
Century TherapeuticsPHILADELPHIA, PA
1 program
1
CNTY-101Phase 11 trial
Active Trials
NCT05336409Terminated28Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Century TherapeuticsCNTY-101

Clinical Trials (1)

Total enrollment: 28 patients across 1 trials

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Start: Jan 2023Est. completion: Jul 202528 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space